跳至主要内容
临床试验/NL-OMON50840
NL-OMON50840尚未招募不适用

Characterization of immune responses in Hepatitis B patients experiencing a flare after stopping nucleot(s)ide analogue therapy - HBV flare

Stichting Leveronderzoek0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • Age between 18 and 65.
  • Previously diagnosed with chronic HBV.
  • Treated with entecavir or tenofovir.
  • Flare defined as ALT>=2x upper limit of normal.
  • Written informed consent.

排除标准

  • Hepatic imaging (ultrasound, CT or MRI) with evidence of hepatocellular
  • Females who are pregnant or breast-feeding.
  • History or other evidence of severe illness, malignancy or any other
  • condition which would make the patient, in the opinion of the investigators,
  • unsuitable for the study.
  • Received prolonged therapy with immunomodulatory agents (e.g.
  • corticosteroids) or biologics (e.g. monoclonal antibody, interferon) within 6
  • months of screening.

研究者

发起方
Stichting Leveronderzoek

相似试验